FDA Approves Updated Aduhelm Prescribing Information to Emphasize Population Studied in Clinical Trials
Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia
CAMBRIDGE, Mass. and TOKYO, July 08, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd....
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials